CLOs on the Move

Cogent Biosciences

www.cogentbio.com

 
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cogentbio.com
  • 200 CambridgePark Drive
    Cambridge, MA USA 02140
  • Phone: 617.945.5576

Executives

Name Title Contact Details

Similar Companies

Tizona Therapeutics

Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.

Organogenesis

Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TYME Inc

TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Selecta Biosciences

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.